

2021 **ANNUAL REPORT**





TABLE OF CONTENTS

01 PRESIDENT MESSAGE / 04

02 EXECUTIVE DIRECTOR
MESSAGE / 05

03 ABOUT LACOG / 06

04 COORDINATING OFFICE / 09

05 LACOG MEMBERS / 10

06 LACOG NUMBERS / 11

07 OUR PARTNERS / 12

08 GENITOURINARY GROUP / 16

09 GYNECOLOGICAL GROUP / 18

10 BREAST GROUP / 20

11 HEAD AND NECK GROUP / 22

12 LUNG GROUP / 24

13 RADIATION GROUP / 26

14 NEURO GROUP / 28

15 GASTROINTESTINAL GROUP / 30

16 GERIATRIC ONCOLOGY GROUP
AND SARCOMA GROUP / 32

17 STUDIES / 34

18 PUBLICATIONS / 38

19 CONFERENCES
AND EVENTS / 42

20 COMMUNICATION / 48

21 PROJETO CURA
INSTITUTE / 50

01

PRESIDENT
MESSAGE**2021: Looking back to jump forward**

It is impossible to avoid a retrospective analysis of the events that so deeply touched us all over the last couple of years. While dealing with the unforeseen, the global but at the same time very personal tragedies that reached every single corner in this world, we need to recognize the endurance, the perseverance and above all the fantastic ability we all have to survive through difficult and challenging times such as these.

It was certainly not very different for most companies, offices, homes or any other activity you might think of. Healthcare systems however were particularly exposed and suffered extra stress. They had to show a little bit more strength than everybody else. We need to recognize that as a general rule, healthcare systems are, under normal circumstances, usually working at their limit, with little room to spare, no extra resources and with critical and chronic manpower shortages. Working like this, it should not be a surprise that the pandemic easily caused a predictable flood of demand that made clearly evident what we always knew and feared as inevitable.

In this situation, clinical research was also affected. Nevertheless, I believe, looking at LACOG's performance, that we were able to keep our heads above water. The lessons learned will be the basis for what I predict to be a strong period of growth over the next few years. Most importantly in this regard, I would like to recognize and thank our central office team for their efforts. They worked with fantastic dedication and relentless team spirit to keep the ball moving. Their enthusiasm and commitment were instrumental and contagious and touched every single one of their interactions with investigators, site personnel, regulatory agencies, ethics committees and sponsors.

This message is mainly directed at them. Their efforts and the success of the group in these difficult times makes me even more certain that we are on the right path and that all our objectives, disseminating more research to patients and investigators in our region will certainly be achieved.

Two particular aspects, central to our future development, deserve a special mention. Both have a common underlying theme: increasing our ability to carry out academic research, a major challenge for research groups all over the world. A challenge that does not have a simple or easy answer.

One aspect to address is to do with LACOG's breakthrough epidemiological studies. Looking at the studies completed recently and those still ongoing, we can see that they represent the critically important generation of independent data with enormous implications for cancer care in Latin America. The second and evolving aspect is the increasing number of investigator-initiated trials that the group is conducting. This reflects the abilities of not only the central team but also of the increasing involvement of investigators and sponsors. Both, the generation of epidemiological data and the generation of independent scientific knowledge are instrumental in building LACOG's credibility to fuel our future expansion.

One final comment is to wholeheartedly and deservedly recognize the regional research and advocacy community and particularly all members of the LACOG family. We were recently pleasantly surprised with the approval of a breast cancer project under the PRONON program. While this was a team effort, it is only fair to acknowledge the determination of the Instituto Projeto CURA led by Fernanda Schwyter and her team, whose work and example is creating a future of unforeseen possibilities for all involved in cancer research in Latin America.

After fielding what we have gone through over the last few months, I am positive that the future is very bright and full of achievements and success for the LACOG family!

A successful 2022 to all.

Dr. Carlos Barrios

A year of growth and achievements

In 2021, LACOG contributed with two important publications in The Lancet Oncology to improve cancer care in Latin America. The first manuscript Cancer control in Latin America and the Caribbean: recent advances and opportunities to move forward highlighted potential interventions that can advance cancer care in the region by overcoming existing challenges. Despite cancer being a major public health problem, Latin America and the Caribbean have had some advances in cancer control in the last years. Patient navigation programs have been implemented in some countries and have proven to be useful for reducing health system access delays and favoring early-stage diagnoses. Additionally, preventive strategies have been implemented in the region, such as tobacco control (all nations in the region have enacted legislation to enforce smoke-free public spaces) and HPV control (most Latin American countries introduced national HPV vaccination programs successfully - 73% of eligible girls and women have received the first HPV vaccine dose within 28 countries). The second manuscript Perspectives on emerging technologies, personalised medicine, and clinical research for cancer control in Latin America and the Caribbean discuss how the implementation of technologies can help cancer control in the region. In the past years, technological advances have permitted a greater proportion of patients to be remotely accessible by improving access to screening programs and diagnostic tests, facilitating the referral process of patients, optimizing access to oncologic treatments, implementing mobile health interventions and virtual patient navigation programs.

Additionally, there has been an improvement in regulatory processes and site qualification which led to a greater participation of LATAM in international clinical research.

Another achievement of LACOG in 2021 was the partnerships between LACOG and international research groups. LACOG became partner of the Southwest Oncology Group (SWOG), which will allow the conduction of international studies in Latin America. Besides that, the partnership with EORTC was also successful. The study PEACE-III initiated in 2021 in Brazil with great patient recruitment, which allowed participant prostate cancer patients to receive standard-of-care treatment options. The objective of such partnerships is to extend international cooperation to provide LACOG investigators the opportunity to participate in studies conducted worldwide. Moreover, these partnerships allow LACOG to expand its portfolio of clinical trials, resulting in the opportunity for Latin-American patients to participate in clinical research with the most advanced cancer treatments.

The increase in the conduction and participation in clinical and epidemiological research of LACOG in 2021 has led to an expansion in its physical structure and greater professional qualification of its employees. Hence, the increase in quality and agility in the whole study process.

Dr. Gustavo Werutsky

02

EXECUTIVE
DIRECTOR
MESSAGE




03 ABOUT LACOG

LACOG wants to bring the world’s attention to the diversity of cancer patients in Latin America

Latin America has more than 600 million people and 1.3 million new cases of cancer. However, only 4% of clinical cancer trials are ongoing in the region. LACOG - Latin American Cooperative Oncology Group is the first multinational cooperative group in Latin America that is exclusively dedicated to clinical and translational cancer research. The group was founded 12 years ago by medical oncologists who wanted to improve clinical research in the region.

To promote and develop cancer research for our patients, LACOG has built a credible platform, supported by the skilled efforts and dedication of our investigators from all over Latin America. The main objectives of the group are to help promote innovative studies that can have an impact on the lives of cancer patients, to contribute to the generation of real-world data and foster the growth of a network of investigators. LACOG conducts epidemiological studies and generates data on the patients’ characteristics, based on real-life treatments and outcomes. The group also carries out clinical research into new drugs for various pathologies, many of which are conducted in partnership with different collaborative groups worldwide.

Currently, LACOG has 10 groups formed by specialists dedicated to different areas of oncology. The groups are responsible for the development and monitoring of studies and also for supporting educational activities and events. The groups are: breast, gynecological, genitourinary, lung, neuro, head and neck, gastrointestinal, radiation, sarcoma and geriatric oncology.



STUDIES BETWEEN 2009 AND 2021



04

COORDINATING OFFICE

In recent years, LACOG Coordinating Office has built a professional structure which is responsible for conducting epidemiological, clinical and translational research. The LACOG coordinating office is located at Tecnopuc - Pontifícia Universidade Católica do Rio Grande do Sul Science and Technology Park - in Porto Alegre, Brazil, and is responsible for assisting investigators to develop their research concepts and protocols, manage and monitor data and conduct pharmacovigilance and statistical analysis.



Being a member of LACOG allows an investigator not only in Latin America, but also worldwide, which results in the improvement of cancer research in Latin America.

In 2020, LACOG reached a total of 420 members. They contribute by suggesting new studies, supporting ongoing research and publishing papers.

ARGENTINA
28

BRAZIL
319

CHILE
10

CUBA
02

ECUADOR
04

MEXICO
20

PANAMA
02

URUGUAY
02

BOLIVIA
02

COLOMBIA
21

COSTA RICA
05

EL SALVADOR
01

GUATEMALA
05

NICARAGUA
01

PERU
12


VENEZUELA
03



443
MEMBERS



200
HOSPITALS AND RESEARCH SITES




16
COUNTRIES

Argentina, Brazil, Bolivia, Colombia, Chile, Costa Rica, Cuba, El Salvador, Ecuador, Guatemala, Mexico, Nicaragua, Panama, Peru, Uruguay and Venezuela




59
ALREADY PERFORMED AND ONGOING TRIALS



MORE THAN
10.700
SUBJECT PATIENTS



91
STUDIES AND ARTICLES PUBLISHED



MORE THAN
29
EDUCATIONAL EVENTS PERFORMED

LACOG collaborates with national and international collaborative groups, participating in the development and management of epidemiological studies and clinical trials.



LACOG IS MEMBER OF





LACOG GROUPS



GENITOURINARY



GYNECOLOGICAL



BREAST



HEAD AND NECK



LUNG



RADIATION



NEURO



GASTROINTESTINAL



SARCOMA



GERIATRIC ONCOLOGY

CHAIR MESSAGE

Over the year of 2021, the LACOG-GU group worked to increase research activities and educational initiatives in the genitourinary area. The result was a significant improvement in the number of ongoing studies and publications. Moreover, accrual on several studies were finished. The results of such studies are expected to be presented in the near future. One landmark achievement was the oral presentation of the LACOG0415 study (castration-sensitive prostate cancer) at the 2020 Annual ASCO meeting and the subsequent publication of the study results in 2021 in the European Journal of Cancer. Another important publication by the group in 2021 was the analysis of the impact of COVID-19 pandemic on research activities in Latin America. The study was published in the Journal of Global Oncology.

LACOG Genitourinary group studies in 2021

LACOG 0519 - PEACE III - A phase III collaborative trial between EORTC and LACOG evaluating enzalutamide with or without radium-223 for patients with metastatic castration-resistant prostate cancer (mCRPC).

LACOG 0620 - ExBAT trial - a phase II disruptive study that evaluates the the alternating treatment with darolutamide and testosterone cipionate for patients with mCRPC.

LACOG 0515 - A multi-centric database of patients with germ cell tumors, in order to characterize them clinically and pathologically and evaluate treatment results.

LACOG 0217 - IRONMAN - An international registry to evaluate the outcomes in men with advanced prostate cancer.

LACOG 0218 - HERCULES - A phase II trial to assess the use of pembrolizumab combined with based chemotherapy as a first-line therapy in advanced penile cancer.

LACOG 1518 - A molecular epidemiological study on urothelial carcinoma, which finished its expected accrual in 2021 and involved several Latin American countries.


LACOG 1818 - A epidemiological study to examine the outcomes among patients being treated in the public and private healthcare systems.

The highlight of the events promoted by the group was the GU Review 2021, which was a very successful online meeting focused on covering the latest on genitourinary cancer. There were 1547 attendees, including 88 participants from abroad. There were 87 speakers, 13 from overseas. During the GU Review meeting, there was the new LACOG-GU board group nomination in which Dr. Diogo Rosa was nominated as the new chair of LACOG-GU. As a group, we intend to continue expanding not only by concluding and publishing the results of ongoing studies, but also by starting new clinical trials.

Dr. Diogo Assed Bastos

BOARD MEMBERS

Genitourinary Group Chair



Dr. Diogo Assed Bastos

ICESP
Sírio-Libanês Hospital
São Paulo, SP, Brazil



Dr. Diogo Rodrigues Rosa

Educational Director
Oncoclínicas Group RJ
Rio de Janeiro (RJ), Brazil



Dr. Andrey Soares

Scientific Director
The Paulista Center of Oncology
Israelita Albert Einstein Hospital
São Paulo (SP), Brazil



Dr. Fernando Nunes

Secretary
Clion – Oncology Clinic
Salvador (BA), Brazil



Dr. Vinícius Carrera

Executive Director
D'Or Oncology Bahia
Salvador (BA), Brazil



CHAIR MESSAGE

Over the challenging years of 2020 and 2021, the LACOG Gynecological Group took important measurements to ensure its continuing growth. The first collaborative study, SENTICOL III, led to a partnership with the Gynecological Cancer InterGroup (GCIG), the largest international joint-working group in gynecological cancer research.

Another notorious study from the group is the EVITA LATAM, which started in 2021. It aims to assess cervical cancer patients in Latin America. The group is currently working in partnership with the Brazilian Gynecological Tumor Group - EVA, the Gynecological Oncology Group and the GCIG.

In 2021, the group initiated and made progressed towards important studies:

LACOG 0215 - EVITA - A epidemiological study evaluating cervical cancer patients in Brazil. A paper was published in the International Journal of Gynecological Cancer in 2021: Characteristics of patients diagnosed with cervical cancer in Brazil: preliminary results of the prospective cohort EVITA study (EVA001/LACOG 0215).

LACOG 1018 - A phase II trial of Palbociclib plus letrozole combination after progression to second line chemotherapy for women with ER/PR-positive ovarian cancer - PI: Fernanda Damian.

LACOG 0920 - SENTICOL III - A phase III trial to validate the sentinel lymph node biopsy in early cervical - PI: Glauco Baiochi. The study has been approved and is currently recruiting.

LACOG 0820 - EVITA LATAM - An epidemiological study of cervical in Latin America. - PI: Graziela Zibetti Dal Molin. The study started in 2021 and will include research sites from Brazil, Argentina, Guatemala, Mexico, Peru, Republica Dominicana, and Colombia.

CONOR Study - A collaborative epidemiological study that evaluates patients with ovarian cancer who have participated in the Expanded Access Program of Niraparib in Latin America. The study is expected to start in 2022. PI: Angélica Nogueira Rodrigues.

Over the year of 2022, the group aims to expand its international partnerships and also encourage LATAM investigators to be more engaged with Gynecological LACOG Group projects. In addition, the group will be involved in the LATAM Connection project, which will feature an event on Endometrial Cancer.

Dr. Angélica Nogueira Rodrigues

BOARD MEMBERS



Gynecological Group Chair



Dr. Angélica Nogueira Rodrigues

UFMG - Federal University of Minas Gerais
Belo Horizonte (MG), Brazil



Dr. Alfonso Dueñas González

Vice-chair
National Institute of Cancerology
Institute of Biomedical Investigation UNAM
Mexico City, Mexico



Dr. Aknar Freire de Carvalho Calabirch

Secretary
Clínica AMO - Multidisciplinary Support in Oncology
Salvador (BA), Brazil

CHAIR MESSAGE

LACOG Breast Group continues to make progress on breast cancer research in Latin America. The LACOG 0615 - LATINA Breast - "A study to observe patient characteristics, treatment patterns and outcomes in patients with newly developed breast cancer in Latin America" successfully completed its recruitment in August 2021. The study included 3,298 patients from 30 research sites in Brazil, Argentina, Uruguay, Chile, Peru, Colombia, the Dominican Republic, Guatemala and Mexico. This has been a great achievement and the first results from the study are expected to be presented in 2022.

Another important achievement was the approval of NEOSAMBA clinical trial by PRONON (Programa Nacional de Apoio à Atenção Oncológica) which is a tax exemption program to help fund cancer control initiatives. Projeto CURA a charity institution that aims to support LACOG cancer research projects, successfully raised all the money required for the study through donations. The NEOSAMBA study, led by Dr Jose Bines from the Instituto Nacional do Cancer, Brazil, is an ongoing phase 3 randomized clinical trial, that is evaluating anthracycline and taxane treatment sequencing in neoadjuvant settings. It intends to recruit around 500 women in Brazil. In addition, the BRAVE study led by the investigator Dr. Gustavo Werutsky started in 2021. It is a retrospective observational study of patients diagnosed with HR+HER2 breast cancer in Brazil intends to identify the clinical and pathological factors associated with the first-line therapy used in clinical practice. Currently, the breast cancer group is conducting eight studies, four clinical trials and four epidemiological studies. Besides that, LACOG Breast is collaborating with GBECAM, EORTC, ABCSG, Alliance, BIG and Frontier Science Foundation in these.

In terms of publications, Dr. Carla Pavei from the Hospital de Clínicas Porto Alegre, Brazil was the first author of an abstract published at ASCO 2021. It showed that in the AMAZONA III study, elderly patients are commonly detected with breast cancer through symptoms, and that patients over 75 are usually diagnosed with advanced or worse degrees of the disease.

Dr. Gustavo Werutsky on behalf of LACOG Breast Group

BOARD MEMBERS



Breast Group Chair



Dr. Henry Gomez Moreno

INEN - National Institute of Neoplastic Diseases
Lima, Peru



Dr. Max Senna Mano

Vice-chair
The Paulista Center of Oncology
Oncoclínicas Group
São Paulo (SP), Brazil



Dr. Cynthia Mayté Villareal-Garza

Secretary
Breast Cancer Center, Hospital
Zambrano Hellion - TecSalud
Monterrey, Mexico

CHAIR MESSAGE

The LACOG Head and Neck Group was actively involved in many important studies throughout 2021. The group met every month to oversee and discuss the ongoing studies and other activities. There were nine webinars, in which with the GBCP – The Brazilian Group on Head and Neck Cancer, were discussed squamous cell carcinoma, thyroid cancer and supportive care in head and neck cancer were discussed.

In 2021, the Mitotic Spindle Positioning (MISP) for the SMARTKEY study was approved. This is a single-arm, multi-institutional phase two study of a pembrolizumab-based strategy for preserving organs for locally advanced laryngeal cancers. Dr. William William and Dr. Thiago Bueno are the PIs for the study.

Another relevant study of the group is the “Study to assess the quality of life in patients with metastatic head and neck cancer undergoing immunotherapy in Brazil” which is a prospective and multi-institutional study that is ongoing, led by Dr. Marcel Santini

In addition to these studies, Dr. Alan Roger from UNICAMP worked with the group on some important meta-analyses, which were published in 2021, and Dr. Daniel Cohen, from INCA - the National Cancer Institute, – will be running a study “Oral cancer awareness, prevention and referral routes in Brazil”, which is due to start in 2022.

The group also published two articles - “Direct costs associated with the management of mucositis: A systematic review”, in Oral Oncology and “Oral leukoplakia and erythroplakia in young patients: a systematic review” in Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology


The LACOG Head and Neck Group achieved important goals last year, working with the GBCP by conducting studies, promoting professional development and raising awareness to head and neck tumors in Brazil. The group is actively dedicated to improve cancer care in the region.

— *Dr. Aline Lauda Freitas Chaves*

BOARD MEMBERS



Head and Neck Group Chair



Dr. Aline Lauda F. Chaves

DOM Oncology
Divinópolis (MG), Brazil




Dr. William Nassib W. Junior

Co-chair
BP – The Beneficência
Portuguesa of São Paulo
São Paulo



Dr. Luiz Paulo Kowalski

Vice-chair
A. C. Camargo Cancer Center
São Paulo (SP), Brazil



Dr. Gilberto de Castro Júnior

Secretary
ICESP- The Cancer Institute of
the State of São Paulo
São Paulo (SP), Brazil

CHAIR MESSAGE

The LACOG Lung Group with the GBOT - Brazilian Group of Thoracic Oncology – took some important steps towards further growth in 2021. The LACOG 0116 - LATINO LUNG study - “Prospective epidemiological study of metastatic Non-Small Cell Lung Cancer (NSCLC) in Latin America” successfully completed its recruitment in August 2021. The study included 804 patients from 23 research sites in Brazil, Argentina, Colombia and Mexico.

In 2021, the LACOG 2218 - PACIFIC BRAZIL study was initiated and the recruitment of patients began in several Brazilian centers. The single arm, phase 2 trial PACIFIC-BRAZIL will evaluate the use of an intensified, immunotherapy-based regimen in patients with stage III non-small cell lung cancers who are candidates for radiation therapy as the definitive form of treatment. The novel regimen is expected to improve progression-free survival rates, compared to the historical control, which will lead to better long-term outcomes.

In addition, the study GBOT 0118/LACOG 0418 - Comprehensive Genomic Profiling of Brazilian Non-Small Cell Lung Cancer Patients was published in Thoracic Cancer. This is a retrospective study conducted by GBOT and LACOG which involved a descriptive analysis of the somatic genetic profile and co-occurring mutations in patients with diagnosed non-small-cell lung cancer between 2013 and 2018 (NSCLC) in Brazil. This study is highly relevant for the Brazilian people, as it provides information that helps us to understand the prevalence of each mutation in the country, as well as co-occurring mutations.

The LACOG 0118 RELANCE - A retrospective epidemiological study of Locally Advanced Non-Small Cell Lung Cancer was presented as a poster at the IALSC Congress by the principal investigator, Dr. Vladimir Lima. This study aims to collect data on the treatment profile of patients with stage III non-small cell lung cancer, as this data is not currently available in Brazil.

In terms of cancer education, the Annual GBOT Symposium was held online last October. It was an opportunity to present and discuss many topics on thoracic oncology, focusing on a multidisciplinary approach to lung cancer.

We hope that LACOG Lung cancer group continually grow in 2022, with positive impact on prevention, diagnosis, staging and the treatment and rehabilitation of patients.

Dr. Gilberto Castro

BOARD MEMBERS



Lung Group Chair



Dr. Gilberto Castro

ICESP - The Cancer Institute of the State of São Paulo
São Paulo (SP), Brazil



Dr. Ana Gelatti

Vice-chair
The São Lucas da PUCRS Hospital
Porto Alegre (RS), Brazil



Dr. Clarissa Baldotto

Vice-chair
A. C. Camargo Cancer Center
São Paulo (SP), Brazil



CHAIR MESSAGE

2021 was an exceptional year for the LACOG Radiation Group. Our goal is to increase the number of studies being conducted and the number of enrolling patients. Additionally, there were several internal discussions with the objective to develop new projects within the group. Besides that, the relationship with important institutions worldwide was strengthened. This resulted in a paper published in the Green Journal of the European Society for Radiotherapy and Oncology (ESTRO), which describes the new advances in radiation oncology in patients suffering from bone metastases in the context of systemic therapies.

Several studies were initiated in 2021. Among such studies, there were sub analyses of studies headed by other LACOG specialty groups and also epidemiological proposals led by radiation group. Another significant step, was the participation of members from Argentina, Chile and Mexico, which represents an important improvement within the general aims of our research activities.

Dr. Maurício Fraga da Silva

BOARD MEMBERS

Radiation Group Chair



Dr. Maurício Fraga da Silva

The University Hospital
of Santa Maria
Santa Maria (RS), Brazil




Dr. Gustavo Nader Marta

Vice-chair
ICESP
Sírio-Libanês Hospital
São Paulo (SP), Brazil



Dr. Fábio Moraes

Secretary
Radiation Medicine Program -
Princess Margaret Cancer Centre
Toronto, Canada



CHAIR MESSAGE

2021 was a challenging year for everyone, especially for oncology research and educational events. Despite the situation, the LACOG Neuro Group published the initial data of **LACOG 0619** study, which is a multicenter, retrospective study that completed its recruiting in November 2021, with the inclusion of 842 patients. The recruit of such large number of patients was possible due to the work and dedication of all members of the group's board. The study's preliminary result were presented at the American Neuro-Oncology Conference (SNO).

Our intention is to strengthened the group in 2022 and attract multi-center studies to Latin America. We also intend to actively participate in the Latin American Neuro-Oncology Conference (SNOLA).

Dr. Camilla Akemi Felizardo Yamada

BOARD MEMBERS

Neuro Group Chair



Dr. Camilla Akemi Felizardo Yamada

The Beneficência Portuguesa
of São Paulo
São Paulo (SP), Brazil



Dr. Fernando Maluf

Vice-chair
The Beneficência Portuguesa
of São Paulo
São Paulo (SP), Brazil



Dr. Suzana Maria Fleury Malheiros

Secretary
The Israelita Albert Einstein
Hospital
São Paulo (SP), Brazil



CHAIR MESSAGE

The LACOG Gastrointestinal Group was involved in many activities in 2021. The group started a new global registry project on anal cancer in HIV+ patients, completed the LACOG/GTG 1318 study and continued to advance the LACOG 0119 study, by adding new sites for recruiting patients.

In addition, the LACOG/GTG 1318 study was published and presented as a poster at the ESMO 2021 conference. It is a Brazilian, multicenter, retrospective study on the outcomes for patients with localized anal cancer, which involved 148 patients. The study evaluated the effects of the treatment regimen (Nigro vs ACT-II regimen) on the clinical complete response (cCR), disease-free survival (DFS) and colostomy-free survival (CFS) of stage I-III pts, using logistic and Cox regression analyses.

Our biggest challenge for 2022 will continue to be getting funding for investigator-initiated studies, as there are still many difficulties in getting approval for the proposals submitted. We will continue to submit proposals so that further research in the area can be carried out in Latin America.

— *Dr. Rachel Riechelmann*

BOARD MEMBERS

Gastrointestinal Group Chair



Dr. Rachel Riechelmann

A.C. Camargo Cancer Center
São Paulo (SP), Brazil



Dr. Anelisa Coutinho

Vice-chair
Clínica AMO – Multidisciplinary
Support in Oncology
Salvador (BA), Brazil



Dr. Renata D'alpino Peixoto

Secretary
Alemão Oswaldo Cruz Hospital
São Paulo (SP), Brazil


LACOG GERIATRIC ONCOLOGY GROUP



Two new groups started up in 2021 in LACOG: the Geriatric Oncology Group and the LACOG Sarcoma Group. These groups represent two important areas of Oncology and will help create new opportunities for research in Latin America.

The LACOG Geriatric Oncology Group is headed up by its chair Dr. Lucíola Leite de Barros from HCOR, São Paulo, vice-chair Dr. Ludmila Koch, from Israelita Albert Einstein Hospital, São Paulo, and secretary Jurema Telles, from the Instituto de Medicina Integral Professor Fernando Figueira - IMIP in Recife.

Geriatric Oncology Group Chair



Dr. Lucíola Leite de Barros

HCOR
São Paulo (SP), Brazil



Dr. Ludmila Koch

Vice-chair
Israelita Albert
Einstein Hospital
São Paulo (SP), Brazil



Dr. Jurema Telles

Secretary
Instituto de Medicina Integral
Professor Fernando Figueira
Recife (PE), Brazil

LACOG SARCOMA GROUP



The LACOG Sarcoma Group is led by Dr. Roberto Pestana from Israelita Albert Einstein Hospital, São Paulo. Also on the board are Dr. Reynaldo Jesus Garcia Filho from Israelita Albert Einstein Hospital, as vice-chair, and Dr. Rafael Schmerling from HCOR, as secretary of the group.

Sarcoma Group Chair




Dr. Roberto Pestana

Israelita Albert
Einstein Hospital
São Paulo (SP), Brazil



**Dr. Reynaldo
Jesus G. Filho**

Vice-chair
Israelita Albert
Einstein Hospital
São Paulo (SP), Brazil



Dr. Rafael Schmerling

Secretary
HCOR
São Paulo (SP), Brazil

These groups will increase the potential for the development of clinical research in Brazil and other Latin American countries, fostering the network of investigators in the region.

17 LACOG STUDIES

	STUDY NAME	TYPE OF STUDY	SPONSOR / SUPPORT	TITLE	SAMPLE SIZE	COUNTRIES LATAM
BREAST	LACOG 0615 LATINA Breast	Epidemiological	LACOG, Roche	A study to observe patients characteristics, treatment patterns and outcomes in patients with newly diagnosed breast cancer in Latin America.	3.272 patients	Argentina, Brazil, Bolivia, Chile, Colombia, Costa Rica, Cuba, Ecuador, Guatemala, Mexico, Peru, Republica Dominicana Uruguay and Venezuela
	LACOG 0413 Male Breast Cancer	Epidemiological	EORTC	Clinical and biological characterization of Male Breast Cancer: an international EORTC, BIG, TBCRC and NABCG intergroup study.	533 patients (15 patients at LATAM)	Brazil, Mexico and Peru
	GBECAM 0115 AMAZONA III	Epidemiological	LACOG, GBECAM, PRONON	Prospective evaluation of breast cancer at Brazilian institutions - Project AMAZONA III	3.000 patients	Brazil
	LACOG 0715 PALLAS	Clinical Trial	ABCSG, ALLIANCE, LACOG	A randomized phase III trialof palbociclib with adjuvant endocrine therapy versus endocrine therapy alone for hormone receptor positive (HR+)/ human epidermal growth factor receptor 2 (HER2)-negative early breast Cancer	4.600 patients (31 patients at LATAM)	Mexico
	LACOG 2118 ALEXANDRA/ IMpassion 030	Clinical Trial	BIG, AFT, Institut Jules, Bordet, IJB, CTSU, Frontier Science Foundation, Roche, LACOG	A phase III, multicenter, randomized, open-label study comparing Atezolizumab (ANTI-PD-L1 ANTIBODY) in combination with adjuvant Anthracycline/Taxane-based chemotherapy versus chemotherapy alone in patients with operable triple-negative breast cancer.	2.300 patients	Brazil and Mexico
	LACOG 0115 LORELEI	Clinical Trial	LACOG, BIG ABCSG Genentech	A Phase II Randomized, Double-Blind, Parallel Cohort Study of Neoadjuvant Letrozole + GDC-0032 versus Letrozole + Placebo in Post-Menopausal Women with ER+/HER2- Primary Breast Cancer	331 patients (9 patients at LATAM)	Brazil
	LACOG 0419 NEOSAMBA	Clinical Trial	LACOG, GBECAM	Evaluation of Sequencing of Anthracyclines and Taxanes for Locally Advanced HER2-negative Breast Cancer	494 patients	Brazil
	LACOG 0221 BRAVE	Epidemiological	LACOG, GBECAM Novartis	Real-World Data on First-line Treatment of Hormone Receptor-positive, HER2-negative, Metastatic Breast Cancer in Brazil (LACOG 0221) – BRAVE Study	300 patients	Brazil

	STUDY NAME	TYPE OF STUDY	SPONSOR / SUPPORT	TITLE	SAMPLE SIZE	COUNTRIES LATAM
GENITOURINARY	LACOG 0217 IRONMAN	Epidemiological	LACOG, Movember	Prostate Cancer Outcomes: An International Registry to Improve Outcomes in Men with Advanced Prostate Cancer	5.000 patients	Brazil
	LACOG 1818 Prostate Cancer Registry	Epidemiological	LACOG	Survival outcomes in metastatic prostate cancer in the Brazilian population - analysis of individual characteristics and treatment modalities in different national health institutions	590 patients	Brazil
	LACOG 0218 HERCULES	Clinical Trial	LACOG, MSD	A phase II trial of pembrolizumab combined with cisplatin-based chemotherapy as first-line systemic therapy in advanced penile cancer	33 patients	Brazil
	LACOG 0519 PEACE III	Clinical Trial	EORTC, Bayer	A Randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone. PEACE III	560 patients (75 patients at LATAM)	Brazil
	LACOG 0620 ExBAT	Clinical Trial	LACOG, BAYER	Extreme Bipolar Androgen Therapy with Darolutamide and Testosterone Cypionate in Patients with Metastatic Castration-Resistant Prostate Cancer (ExBAT trial)	47 patients	Brazil
	LACOG 0121 PET PSMA	Clinical Trial	LACOG	Retrospective analysis of 68Ga-PSMA-PET in patients with prostate cancer: experience from Brazil	700 patients	Brazil

LUNG	STUDY NAME	TYPE OF STUDY	SPONSOR / SUPPORT	TITLE	SAMPLE SIZE	COUNTRIES LATAM
	LACOG 0116 LATINO LUNG	Epidemiological	LACOG, BMS, Pfizer	Prospective epidemiological study of metastatic Non Small Cell Lung Cancer (NSCLC) in Latin America	727 patients	Argentina, Brazil, Colombia, Mexico and Uruguay
	LACOG 1918 Patient journey ALK	Epidemiological	LACOG, GBOT, Takeda	Patient Journey with advanced lung cancer positive for ALK fusion in Brazil	100 patients	Brazil
	LACOG 2218 PACIFIC BRAZIL	Clinical Trial	LACOG, AstraZeneca	Intensified chemo-immuno-radiotherapy with durvalumab (MEDI4736) for stage III Non-Small Cell Lung Cancers (NSCLCs): a Brazilian Single Arm Phase II study (PACIFIC BRAZIL)	48 patients	Brazil
	LACOG 0120 EAP Durva	Epidemiological	LACOG, GBOT	Durvalumab as maintenance in patients who received chemoradiotherapy for unresectable stage III NSCLC: Real World Data from an Expanded Access Program in Brazil.	36 patients	Brazil

	STUDY NAME	TYPE OF STUDY	SPONSOR / SUPPORT	TITLE	SAMPLE SIZE	COUNTRIES LATAM
GYNECOLOGICAL	LACOG 1018 PALBO in Ovarian Cancer	Clinical Trial	LACOG, Pfizer	Palbociclib plus letrozole combination after progression to second line chemotherapy for women with ER/PR-positive ovarian cancer	43 patients	Brazil
	LACOG 0920 Senticol III	Clinical Trial	Centre Hospitalier Universitaire de Besançon LACOG	International validation study of sentinel node biopsy in early cervical cancer	950 patients (200 Brazil)	Brazil
	LACOG 0820 EVITA LATAM	Epidemiological	LACOG AstraZeneca	EVITA LATAM: Epidemiological Landscape of Cervical Cancer in Latin America	482 patients	Brazil, Mexico, Colombia, Peru, Argentina, Guatemala, Dominican Republic
HEAD AND NECK	LACOG 0319	Epidemiological	LACOG	Quality Of Life Assessment Study In Patients With Metastatic Head And Neck Neoplasia Submitted To Immunotherapy In Brazil	200 patients	Brazil
	LACOG 0720 SMART-KEY	Clinical Trial	LACOG MSD	SMART-KEY: A single-arm, multi-institutional, phase 2 study of a pembrolizumab-based organ preservation strategy for locally advanced larynx cancers	39 patients	Brazil
GASTROINTESTINAL	LACOG 0119 NET	Epidemiological	LACOG, GTG	A multicenter retrospective database on prognostic and predictive factors in patients with neuroendocrine tumors	300 patients	Brazil
NEURO	LACOG 0619 Glioma Registry	Epidemiological	LACOG	Characterization of patients with diffuse gliomas in Brazil	300 patients	Brazil

ARTICLES

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

Francesco Schettini, Nuria Chic, Fara Brasó-Maristany, Laia Paré, Tomás Pascual, Benedetta Conte, Olga Martínez-Sáez, Barbara Adamo, Maria Vidal, Esther Barnadas, Aranzazu Fernández-Martinez, Blanca González-Farre, Esther Sanfeliu, Juan Miguel Cejalvo, Giuseppe Perrone, Giovanna Sabarese, Francesca Zalfa, Vicente Peg, Roberta Fasani, Patricia Villagrasa, Joaquín Gavilá, Carlos H Barrios, Ana Lluch, Miguel Martín, Mariavittoria Locci, Sabino De Placido, Aleix Prat

NPJ Breast Cancer. 2021 Jan 4;7(1):1

Comprehensive genomic profiling of Brazilian non-small cell lung cancer patients (GBOT 0118/LACOG0418)

Eldsamira Mascarenhas, Ana Caroline Gelatti, Luiz Henrique Araújo, Clarissa Baldotto, Clarissa Mathias, Mauro Zukin, Gustavo Werutsky, Patricia Pacheco, Rafaela Gomes, Gilberto de Castro Jr, Vladimir Cláudio Cordeiro de Lima

Thoracic Cancer, 13 December 2020

Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

Erica L Mayer, Amylou C Dueck, Miguel Martin, Gabor Rubovszky, Harold J Burstein, Meritxell Bellet-Ezquerro, Kathy D Miller, Nicholas Zdenkowski, Eric P Winer, Georg Pfeiler, Matthew Goetz, Manuel Ruiz-Borrego, Daniel Anderson Zbigniew Nowecki, Sibylle Loibl, Stacy Moulder, Alistair Ring, Florian Fitzal, Tiffany Traina, Arlene Chan, Hope S Rugo, Julie Lemieux, Fernando Henao, Alan Lyss, Silvia Antolin Novoa, Antonio C Wolff, Marcus Vetter, Daniel Egle, Patrick G Morris, Eleftherios P Mamounas, Miguel J Gil-Gil, Aleix Prat, Hannes Fohler, Otto Metzger Filho, Magdalena Schwarz, Carter Du Frane, Debora Fumagalli, Kathy Puyana Theall, Dongrui Ray, Cynthia Huang, Maria Koehler, Christian Fesl, Angela De Michele, Michael Gnant

The Lancet Oncology. Volume 22, Issue 2, February 2021

Sequential therapies for advanced urothelial cancer: Hope meets new challenges

Daniel Herchenhorn, Vinicius Freire, Thamires Oliveira, Juliana Tarouquella

Crit Rev Oncol Hematol. 2021 April

The role of 68 Gallium-prostate-specific membrane antigen positron emission tomography on staging of high-risk localized prostate cancer: for all high-risk patients or would it be better to select them?

Fernando Sabino M Monteiro, Juçara Motta Serafim Eliam, Rafaela Gomes de Jesus, Pedro Cavalcante, Gustavo do Vale Gomes, Bruno Hochhegger, Vinicius K Gonçalves, Laura Von Wallwitz Freitas, Diego H Roman, Andre Poisl Fay

Prostate Int. 2021 Mar;9(1):54-59

Moderate hypofractionation for salvage radiotherapy (HYPO-SRT) in patients with biochemical recurrence after prostatectomy: A cohort study with meta-analysis

Gustavo Arruda Viani, Andre Guimaraes Gouveia, Elton Trigo Teixeira Leite, Fabio Ynoe Moraes

Radiother Oncol. 2022 Mar 11;171:7-13.

Challenge of Incorporating New Drugs for Breast Cancer in Brazil: A Proposed Framework for Improving Access to Innovative Therapies

Carlos Barrios, Ruffo Freitas-Junior, Sandro Martins, Jose Bines, Maria Del Pilar Estevez-Diz, Maira Caleffi

Journal of Clinical Oncology no. 7. April 6, 2021

ARTICLES

Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial

Sibylle Loibl, Frederik Marmé, Miguel Martin, Michael Untch, Hervé Bonnefoi, Sung-Bae Kim, Harry Bear, Nicole McCarthy, Mireia Melé Olivé, Karen Gelmon, José García-Sáenz, Catherine M. Kelly, Toralf Reimer, Masakazu Toi, Hope S. Rugo, Carsten Denkert, Michael Gnant, Andreas Makris, Maria Koehler, Cynthia Huang-Bartelett, Maria Jose Lechuga Frean, Marco Colleoni, Gustavo Werutsky, Sabine Seiler, Nicole Burchardi, Valentina Nekljudova, Gunter von Minckwitz

Journal of Clinical Oncology. April 01, 2021.

Impact of the COVID-19 Pandemic on Oncology Clinical Research in Latin America (LACOG 0420)

Aline B Lara Gongora, Gustavo Werutsky, Denis L Jardim, Angelica Nogueira-Rodrigues, Carlos H Barrios, Clarissa Mathias, Fernando Maluf, Rachel Riechelmann, Maurício Fraga, Henry Gomes, William N William, Camilla A F Yamada, Gilberto de Castro Jr, Daniela D Rosa, Andreia C de Melo, Raul Sala, Eva Bustamante, Denisse Bretel, Oscar Arrieta, Andrés F Cardona, Diogo A Bastos

JCO Glob Oncol. 2021 Apr;7:649-658.

Real-world data on neoadjuvant endocrine therapy in ER-positive/HER2-negative breast cancer

Leonardo Roberto da Silva, Camila Annicchino de Andrade, Fabrício Brenelli, Susana Ramalho, Tomás Reinert, Alessandra Borba Anton de Souza, Ana Elisa Ribeiro da Silva, Maria Beatriz de Paula Leite Kraft, Vivian Castro Antunes de Vasconcelos, Antônio Luiz Frasson, Renato Zochio Torresan, Cesar Cabello, Matthew J Ellis, Luiz Carlos Zeferino

Breast Cancer Res Treat. 2021 Apr;186(3):753-760

Consensus on the Screening, Staging, Treatment, and Surveillance of Localized, Recurrent, and Metastatic Prostate Cancer: The First Global Prostate Cancer Consensus Conference for Developing Countries

Fernando Cotait Maluf, Silke Gillessen

JCO Glob Oncol. 2021 Apr;7:512-515.

ConsensusforTreatmentofMetastatic Castration-Sensitive Prostate Cancer: Report From the First Global Prostate Cancer Consensus Conference for Developing Countries (PCCCDC)

Fernando Cotait Maluf , Felipe Moraes Toledo Pereira, Pedro Luiz Serrano Uson Jr, Diogo Assed Bastos, Diogo Augusto Rodrigues da Rosa, Evanius Garcia Wiermann, Fábio A Schutz, Fábio Roberto Kater, Fernando Nunes Galvão de Oliveira, Fernando Sabino Marques Monteiro, Fernando Vídgal de Pádua, Francisco Javier Orlandi, Helena Paes de Almeida Saito, Mouna Ayadi, Pamela Salman Boghikian, Ray Manneh Kopp, Ricardo Saraiva de Carvalho, Rodrigo Nogueira de Fogace, Sandro Roberto de Araújo Cavallero, Sergio Aguiar, Vinicius Carreira Souza, Silke Gillessen Sommer

JCO Glob Oncol. 2021 Apr;7:550-558

Consensus on Treatment and Follow-Up for Biochemical Recurrence in Castration-Sensitive Prostate Cancer: A Report From the First Global Prostate Cancer Consensus Conference for Developing Countries

Fernando S M Monteiro, Fabio A Schutz, Igor A P Morbeck, Diogo A Bastos, Fernando V de Padua, Leonardo A G A Costa, Manuel C Maia, Jose A Rinck Jr, Stenio de Cassio Zequi, Karine M da Trindade, Wladimir Alfer Jr 16, William C Nahas, Lucas V Dos Santos, Robson Ferrigno, Diogo A R da Rosa, Juan P Sade, Francisco J Orlandi, Fernando N G de Oliveira, Andrey Soares

JCO Glob Oncol. 2021 Apr;7:538-544

A Systematic Review and Meta-Analysis of the Role of Immune Checkpoint Inhibitors (ICI) as Adjuvant Treatment for Localized High-Risk Muscle-Invasive Urothelial Carcinoma (MIUC)

Fernando Sabino M Monteiro, Andrey Soares, Vinicius Carrera Souza, Rubens Cópia Sperandio, Enrique Grande, Matteo Santoni, Andre Poisl Fay, Andre Deeke Sasse

Clin Genitourin Cancer. 2022 Apr 25;S1558-7673(22)00085-4.

Moderately hypofractionated post-operative radiation therapy for breast cancer: Systematic review and meta-analysis of randomized clinical trials

Gustavo Nader Marta, Rachel Riera, Rafael Leite Pacheco, Ana Luiza Cabrera Martimbianco, Icro Meattini, Orit Kaidar-Person, Philip Poortmans

Breast. 2022 Apr;62:84-92.

Treatment of Localized and Locally Advanced, High-Risk Prostate Cancer: A Report From the First Prostate Cancer Consensus Conference for Developing Countries

Raja Khauli, Robson Ferrigno, Gustavo Guimarães, Muhammad Bulbulan, Pedro Luiz Serrano Uson Junior, Bernardo Salvajoli, Daniel Moore Freitas Palhares, Douglas Racy, Erlon Gil, Fernando Freire de Arruda, Gustavo Caserta Lemos, Gustavo Franco Carvalhal, Icaro Thiago de Carvalho, Igor Austin Fernandes Martins, Ivan Frederico Pinto Gimpel, João Victor Salvajoli, José Luis Chambo, José Pontes Jr, Leopoldo Alves Ribeiro Filho, Lucas Nogueira, Marcelo Roberto Pereira Freitas, Marcelo Wroclawski, Marco Antonio Arap, Marcus Vinicius Sadi, Rafael Coelho, Rafael Gadia, Rodrigo Antonio Ledezma Roja, Rodrigo de Moraes Hanriot, Ronaldo Baroni, Stenio Zequi, William Carlos Nahas, Wladimir Alfer Jr, Fernando Cotait Maluf

JCO Glob Oncol. 2021 Apr;7:530-537

Highlights of the 17th St Gallen International Breast Cancer Conference 2021: customising local and systemic therapies

Tomás Reinert, Alessandra Borba Anton de Souza, Guilherme Parisotto Sartori, Fernando Mariano, Carlos Henrique Barrios

Ecancermedalscience. 2021 May 18;15:1236.

Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D)

Alvaro Moreno-Aspitia, Eileen M Holmes, Christian Jackisch, Evandro de Azambuja, Frances Boyle, David W Hillman, Larissa Korde, Debora Fumagalli, Miguel A Izquierdo, Ann E McCullough, Antonio C Wolff, Kathleen I Pritchard, Michael Untch, Sébastien Guillaume, Michael S Ewer, Zhimin Shao, Sung Hoon Sim, Zeba Aziz, Georgia Demetriou, Ajay O Mehta, Michael Andersson, Masakazu Toi, Istvan Lang, Binghe Xu, Ian E Smith, Carlos H Barrios, Jose Baselga, Richard D Gelber, Martine Piccart-Gebhart, ALTTO Steering Committee and Investigators

Eur J Cancer. 2021 May;148:287-296.

Erdafitinib treatment in Brazilian patients with metastatic urothelial carcinoma (mUC): real-world evidence from an Expanded Access Program

Fernando Sabino M Monteiro, Adriano Gonçalves E Silva, Andrea Juliana P de S Gomes, Carolina Dutra, Naira Oliveira Ferreira, Rodrigo Coutinho Mariano, Fabio A Schutz

Ther Adv Med Oncol. 2021 May 18;13:17588359211015499

Cost-effectiveness of breast, lung, colon, prostate and cervical cancer outcomes in Brazil: a worldwide comparison

Rodrigo Pellegrini, Tomás Reinert, Carlos Henrique Barrios

Ecancermedalscience. 2021 Jun 7;15:1243.

Induction Chemotherapy for Advanced Oral Cavity Cancer

Thiago Bueno de Oliveira, Gustavo Nader Marta, Gilberto de Castro Junior, Luiz Paulo Kowalski

Curr Oncol Rep. 2021 Aug 27;23(11):129.

Perspectives on the Systemic Staging in Newly Diagnosed Breast Cancer

Tomás Reinert, Alessandra Borba Anton de Souza, Mahira Lopes Rosa, Sabrina Richter Bedin, Carlos Henrique Barrios

Clin Breast Cancer. 2021 Aug;21(4):309-316.

Brazilian Validation of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group (QLG) Computerised Adaptive Tests (CAT) Core

Gustavo Nader Marta, Tomás Y T de Souza, Alice R N de Souza E Silva, Ana Paula A Pereira, David R Ferreira Neto, Rie N Asso, Fabiana A M Degrande, Guilherme Nader-Marta, Maurício F da Silva, Rafael Gadia, Samir A Hanna, Bernhard Holzner 5, Everardo D Saad, Morten Aagaard Petersen

Curr Oncol. 2021 Aug 31;28(5):3373-3383

Tissue-agnostic drug approvals: how does this apply to patients with breast cancer?

Luiza N Weis, Sara M Tolaney, Carlos H Barrios, Romualdo Barroso-Sousa

NPJ Breast Cancer. 2021 Sep 13;7(1):120

Stereotactic body radiotherapy to treat breast cancer oligometastases: A systematic review with meta-analysis

Gustavo A Viani, Andre G Gouveia, Alexander V Louie, Martin Korzeniowski, Juliana F Pavoni, Ana Carolina Hamamura, Fabio Y Moraes

Radiother Oncol. 2021 Nov;164:245-250.

Open questions and controversies in the systemic treatment of breast cancer

Carlos Henrique Barrios, Tomás Reinert

Curr Opin Oncol. 2021 Nov 1;33(6):591-596.

Perspectives on emerging technologies, personalised medicine, and clinical research for cancer control in Latin America and the Caribbean

The Lancet Oncology Volume 22, Issue 11, November 2021, Pages e488-e500"

Cancer control in Latin America and the Caribbean: recent advances and opportunities to move forward

Carlos H Barrios, Gustavo Werutsky, Alejandro Mohar, Ana S Ferrigno, Bettina G Müller, Brittany L Bychkovsky, Carlos José Castro, Claudia J Uribe, Cynthia Villarreal-Garza, Enrique Soto-Perez-de-Celis, Francisco Gutiérrez-Delgado, Ji Seok Kim, Julia Ismael, Lucia Delgado, Luiz A Santini, Nelson Teich, Pamela C Chavez, Pedro E R Liedke, Pedro Exman, Romualdo Barroso-Sousa, Stephen D Stefani, Suyapa A Bejarano Cáceres, Taiane F Rebelatto, Tania Pastrana, Yanin Chavarri-Guerra, Yolanda Vargas, Eduardo Cazap

The Lancet Oncology Volume 22, Issue 11, November 2021, Pages e474-e487"

Epidemiological characteristics and survival of patients with diffuse glioma in Brazil: preliminary results of a multicentric retrospective study - LACOG 0619

Camilla Yamada, Carolina Vasques, Rodrigo Coutinho, Marcos Maldaun, Clarissa Baldotto, Fabiana Viola, Fernando Maluf, Vanessa Santos, Carolina Pessoa, Patrícia Pacheco, Danielli Matias, Daniela Oliveira, Fernanda Peria, Rafaela de Jesus, Taiane Rebelatto, Suzana Malheiros

Neuro-Oncology, Volume 23, Issue Supplement_6, November 2021, Pages vi86–vi87

ARTICLES

A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415)

Fernando C. Maluf, Fabio A. Schutz, Eduardo H. Cronemberger, Murilo de A. Luz, Suelen P. S. Martins, David Q. B. Muniz, Diogo A. Bastos, Flavio M. Cárcano, Oren Smaletz, Andrey Soares, Fábio A. Peixoto, Andrea J. Gomes, Felipe M. Cruz, Fabio A. Franke, Daniel Herchenhorn, Telma M. dos Santos, Vanessa de C. Fabricio, Rosemarie Gidekel, Gustavo Werutsky, Rafaela G. de Jesus, Vinicius C. Souza, André P. Fay

European Journal of Cancer - Volume 158, November 2021, Pages 63-71

Characteristics of patients diagnosed with cervical cancer in Brazil: preliminary results of the prospective cohort EVITA study (EVA001/LACOG 0215)

Angélica Nogueira Rodrigues, Andréia Cristina de Melo, Aknar Freire de Carvalho Calabrich, Eduardo Cronenberger, Kátia Luz Torres, Fernanda Damian, Rachel Cossetti, Carla Ramerí Alexandre Silva de Azevedo, Allex Jardim da Fonseca, Yeni Nerón, João Nunes, André Lopes, Felipe Thomé, Renato Leal, Giuliano Borges, Arthur Ferreira da Silva, Matheus Führr Rodrigues, Paulo Ricardo Santos Nunes Filho, Facundo Zaffaroni, Raquel Dal Sasso Freitas, Gustavo Werutsky, Fernando Maluf

Int J Gynecol Cancer. 2022 Feb;32(2):141-146. Epub 2021 Dec 29.

Real-world Data on First-line Systemic Therapy for Hormone Receptor-positive HER2-negative Metastatic Breast Cancer: A Trend Shift in the Era of CDK 4/6 Inhibitors

Gustavo Werutsky 1, Tomás Reinert 2, Mahira Lopes Rosa 3, Carlos Henrique Barrios 2

Clin Breast Cancer. 2021 Dec;21(6):e688-e692.

ABSTRACTS

Health-related quality-of-life (HRQoL) analysis from a randomized phase II trial of androgen signaling inhibitors with or without androgen deprivation therapy (ADT) for castration-sensitive prostate cancer: LACOG 0415

Andrey Soares, Diogo Assed Bastos, Fabio A. B. Schutz, Eduardo Cronemberger, Murilo Luz, Suelen P. S. Martins, David Queiroz Borges Muniz, Flavio Mavignier Carcano, Oren Smaletz, Fábio A Peixoto, Andrea Juliana Gomes, Felipe Melo Cruz, Fabio Andre Franke, Daniel Herchenhorn, Rosemarie Gidekel, Taiane Francieli Rebelatto, Rafaela Gomes, Vinicius Carrera Souza, Andre P. Fay, Fernando C. Maluf

J Clin Oncol 39, 2021 (suppl 6; abstr 64)

Clinical-pathological characterization and outcomes of metastatic urothelial cancer in Latin America: Retrospective and translational multicenter database (LACOG 1518)

Vinicius Carrera Souza, Murilo Luz, Diogo Assed Bastos, Marcelo Roberto Pereira Freitas, Breno Dauster Pereira E Silva, Fernando Sabino M. Monteiro, Roni Fernandes, Manuel Caitano, Karine Trindade, Lucas Nogueira, Daniel Herchenhorn, Juan Sade, Fernando Nunes Galvão de Oliveira, Andre P. Fay, Gustavo Werutsky, Fernando C. Maluf, Vanessa Carvalho Fabricio, Rosemarie Gidekel, Patricia Pacheco, Andrey Soares

J Clin Oncol 39, 2021 (suppl 6; abstr TPS497)

Real-world outcomes from cisplatin versus mitomycin plus fluoropyrimidine and radiation for localized squamous cell carcinoma of the anus (SCCA) - LACOG 1318

R.P. Riechelmann, A.K. Coutinho, G.S. Fernandes, R.F. Weschenfelder, D.R. Rocha Filho, L.A. Schlittler, J.F. Rego, R.G. de Jesus, G.C.D.L. Gossling, R.D. Peixoto

Annals of Oncology (2021) 32 (suppl_5): S530-S582. 10.1016/annonc/annonc698

Retrospective Epidemiological study of Locally Advanced Non-small cell Lung CancEr patients in Brazil – RELANCE (LACOG 0118)

Vladmir Cordeiro De Lima

WCLC 2021

Real-world outcomes from cisplatin versus mitomycin plus fluoropyrimidine and radiation for localized squamous cell carcinoma of the anus (SCCA) - LACOG 1318

R.P. Riechelmann, A.K. Coutinho, G.S. Fernandes, R.F. Weschenfelder, D.R. Rocha Filho, L.A. Schlittler, J.F. Rego, R.G. de Jesus, G.C.D.L. Gossling, R.D. Peixoto

Annals of Oncology (2021) 32 (suppl_5): S530-S582. 10.1016/annonc/annonc698

Sociodemographic and clinicopathologic features of elderly breast cancer patients in Brazil: A sub-analysis of AMAZONA III study (GBCAM 0115).

Carla Pavei, Daniela D. Rosa, Jose Bines, Gustavo Werutsky, Carlos H. Barrios, Eduardo Cronemberger, Sergio D. Simon, Geraldo S. Queiroz, Vladmir C. Cordeiro De Lima, Ruffo Freitas-Junior, Heloisa M. Resende, Susanne C. Costa, Tomas Reinert, Brigitte M. Van Eyll, Vanessa D. Bertoni, Yeni V. Neron, Nicolas Lazaretti, Rafaela Gomes, Taiane F. Rebelatto, Pedro E. Liedke

J Clin Oncol 39, 2021 (suppl 15; abstr e12603

Epidemiological characteristics and outcomes of patients with diffuse glioma in Brazil: preliminary results of a multicentric retrospective study - LACOG 0619 study

Camilla Yamada

SNO 2021

19

CONFERENCES AND EVENTS




The Brazilian Breast Cancer Conference 2021 LACOG/GBECAM and Best of SABCS® Brazil

The Brazilian Breast Cancer Conference 2021 took place between March 9th and 11th, alongside the official licensed event, Best of SABCS Brazil. This event was organized by LACOG and the Brazilian Group for Breast Cancer Studies (GBECAM) and was broadcast online. Experts from across Brazil and from other countries came together to debate the main developments in the diagnosis and treatment of breast cancer.

The first day of the event was dedicated to the Best of SABCS Brazil, in which the main highlights of the San Antonio Breast Cancer Symposium were presented to the participants. The main themes addressed at that meeting were introduced and their relevance to Brazil was discussed. On the other days, the event had modules dedicated to the treatment of the early and metastatic disease, including some new ideas on the use of molecular and genetic breast cancer tests, as well as some major advances in surgery, radiotherapy and systemic treatments and their impact on clinical practice.

The conference had 26 renowned speakers from Brazil and abroad and 1,737 attended the online scientific program from various states in Brazil over the three days.



London Global Cancer Week

In collaboration with the LACOG Genitourinary Group, the NCCN - National Comprehensive Cancer Network co-hosted the webinar “Management of Prostate Cancer for Latin America”, which was focused on key updates of the NCCN Guidelines for Prostate Cancer to optimize clinical management.

The webinar was held on March 23rd, and was attended by 377 people from 18 countries who watched the online scientific program. The program was presented by six leading experts from Latin America and the United States.





Management of Prostate Cancer for Latin America Webinar LACOG and NCCN

In collaboration with the LACOG Genitourinary Group, the NCCN - National Comprehensive Cancer Network co-hosted the webinar “Management of Prostate Cancer for Latin America”, which focused on key updates of the NCCN Guidelines for Prostate Cancer to optimize clinical management.

The webinar was held on March 23rd, and was attended by 377 people from 18 countries who watched the online scientific program. The program was presented by six leading experts from Latin America and the United States.

The HOLA COVID-19 study: Evaluating the impact of caring for patients with COVID-19 on cancer care delivery in Latin America.

Results:	Control for patients with COVID-19	Did not care for COVID-19	p-value
Completed by a team effective CT regimen with less side effects	50	28	0.000
Accepted CT in patients previously on treatment	28	18	0.001
Accepted CT in patients previously on treatment or stopped treatment	40	28	0.000
Completed by a team effective CT regimen	28	18	0.000
Completed by a team effective CT regimen	40	28	0.001
Completed by a team effective CT regimen	40	28	0.001
Completed by a team effective CT regimen	40	28	0.001
Completed by a team effective CT regimen	40	28	0.001
Completed by a team effective CT regimen	40	28	0.001
Completed by a team effective CT regimen	40	28	0.001





Best of ASCO 2021

The Brazilian edition of Best of ASCO 2021, organized by LACOG and the Instituto Ética, took place on June 14th to 16th, online. The event was attended by 1,935 participants from 23 Brazilian states and other Latin American countries.

The conference presented the main studies from ASCO in 2021. 32 speakers from Brazil and from abroad presented 49 abstracts on the Genitourinary, Skin Cancer and Sarcomas, Gastrointestinal, Hematology, Breast, Gynecology, Lung, Head and Neck and Neuro modules.

The Brazilian Edition of Best of ASCO is officially licensed by ASCO, which organizes the most important oncology conference in the world and is committed to improving the rate of progress in the fight against cancer.



V GU Review International Symposium 2021 III Multiprofessional Symposium

The V GU Review International Symposium 2021 and the III Multiprofessional Symposium, organized by the LACOG Genitourinary Group were held on 14th, 15th and 16th October 2021. 931 people and 87 speakers participated in the events which took place online.

The program covered the latest developments in the treatment and diagnosis of genitourinary neoplasms, and featured important topics on bladder, prostate and kidney cancer, which referred to important aspects related to treatments, studies and research into the diseases.

The III Multiprofessional Symposium was dedicated to nurses, pharmacists, psycho-oncologists, physiotherapists and nutritionists. The program included topics such as the infusion of antineoplastic drugs, the management of local infusion reactions and the impact of the Conference of the American Clinical Oncology Society on practical care.





One of the main objectives of LACOG's communications is to disseminate scientific knowledge and clinical research among Latin American physicians, giving support to the initiatives and achievements of investigators in the region. In 2021, we adapted all communication strategies to the digital format, and managed to reach people and places in Latin America in ways that would not be possible in person.

Educational Events

Six online educational events were held in 2021,, covering different areas of oncology. Over 5500 people from 18 countries participated in the conferences, as well as 193 speakers. Multidisciplinary debates, presentations of abstracts from international congresses, new treatments and other topics were discussed during the programs between speakers and the audience, bringing knowledge about the most up-to-date clinical research in the world.

Recruitment campaigns for studies

We conducted a number of recruitment campaigns on social networks for LACOG studies, along with Projeto CURA and the Vencer o Câncer Institute, to inform patients about the clinical research ongoing in the country. We developed the first website for a study, LACOG 0218 - HERCULES, to help inform and provide reliable information to Brazilian patients with penile cancer.

Groups and Publications

We share publications from LACOG members and groups through LACOG's social networks - Instagram, Facebook, LinkedIn, Twitter and Youtube, as well as new studies, activities, events and other achievements made by investigators. Our online followers increased by 1437 in our digital platforms, and we improved the LACOG website by adding maps for each study to show the location of those research sites that are recruiting patients.

2021 was an intense and challenging year for communications, and in 2022 we hope to implement some new projects related to medical education and initiatives to improve cooperation between LACOG members.

— *Patrícia Müller Weber - Communications Coordinator*





Projeto cura.

Juntos,
pesquisando
a cura
do câncer.

The Renata Thormann Procianoy Award



The winning research project for the 3rd Renata Thormann Procianoy award, established by the Projeto Cura Institute, was announced on June 17th, 2021. The investigation, entitled “Randomized study of the use of an electric hand warmer compared to observation to reduce the discomfort when cooling the scalp to prevent chemotherapy-induced alopecia”, was led by Dr. Luciana Landeiro and studied ways to make it more comfortable for breast cancer patients who were receiving scalp cooling as part of their chemotherapy treatment, in order to reduce Alopecia Areata (hair loss).

The award ceremony took place on the 16th and was part of the Best of ASCO 2021 Annual Meeting – Brazil Edition.

PATIENTS’ FORUM “INSIDE CANCER”

On October 6th, the Projeto Cura Institute held a Patients’ Forum “Inside Cancer - Breast Cancer Edition”. This was an opportunity for patients and the general public, to have their questions answered by experts and for managers in NGOs to learn more about the subject so that they can disseminate accurate information.

The Forum focused on patients, family members, healthcare workers and NGO managers and was intended to inform and educate them on the disease and its treatment and to explain some of the latest research in Brazil.

The event had six general sessions, one for questions and a main debate on research. It lasted for three and a half hours; thirteen experts took part and 300 people signed up for it!

Fundraising campaign NeoSamba - Phase 3

After managing to raise the necessary funds to register of the Neosamba study, the Projeto Cura Institute ran a further fundraising campaign to support this Brazilian study that evaluates a new sequencing of the treatment of HER2-negative breast cancer.

The results of this study should have an immediate global impact. It is especially significant for young women and women diagnosed with breast cancer in developing countries.

The actress Patrícia Pillar was the Ambassador for the campaign, which was titled "Together we can be stronger than cancer", volunteering her support with publicity shots and video.



Projeto Cura receives PRONON funding approval

On November 18th, the Ministry of Health published, in the Official Gazette, its approval for the PRONON application by the NeoSamba Study. This is a Brazilian research study that studies a new sequencing of the treatment of HER2-negative breast cancer.

The application by GBECAM-LACOG was made in 2019 at the initiative of the Projeto Cura Institute, who played a fundamental role in identifying the opportunity, adapting the project, making the application and following up the public notice with the Ministry of Health.

Following the approval in November 2021, it took a few weeks to raise the approved amount thanks to the efforts.

It was an important achievement, since may help support other awareness and funding initiatives by the Projeto Cura Institute.



SBOC - The 22nd Brazilian Conference on Clinical Oncology

The Projeto Cura Institute took part in the 22nd Brazilian Conference on Clinical Oncology, which was held in Salvador-BA from November 17th to 20th, 2021.

The President of the Projeto Cura Institute, Fernanda Schwyter, was a member of the panel on the Fundamentals of Clinical Research: innovative initiatives in Advocacy in Brazil focusing on Clinical Research.

The conference, which marked the resumption of in-person events, was an opportunity for the leading experts to meet.

15th Edition of Breast Cancer Event - Gramado

The Projeto Cura Institute participated in the 15th Edition of Breast Cancer Gramado Event. Its main objective was to encourage communication between those who work in the various different areas that care for patients with breast cancer, and to encourage them to exchange ideas and experience, with the aim to improve the wellbeing of breast cancer patients.

The President of the Projeto Cura Institute, Fernanda Schwyter, was a member of the Hot Topics panel on December 3rd, Dr. Daniela Rosa acted as a moderator.





@lacog.org.br



/lacog



/lacog.org



/bit.do/lacog



@lacogg